Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Edesa Biotech, Inc. EDSA
$0.91
-$0.03 (-3.50%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
18955472.00000000
-
week52high
2.81
-
week52low
0.76
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.78728200
-
EPS
-0.83000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 20 дек 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| van der Velden Peter | D | 150275 | 12895 | 10 янв 2023 г. |
| van der Velden Peter | D | 1625133 | 139450 | 10 янв 2023 г. |
| van der Velden Peter | D | 163170 | 12284 | 09 янв 2023 г. |
| van der Velden Peter | D | 1764583 | 132845 | 09 янв 2023 г. |
| Nijhawan Pardeep | A | 114131 | 114131 | 02 ноя 2022 г. |
| Nijhawan Pardeep | A | 228262 | 228262 | 02 ноя 2022 г. |
| Nijhawan Pardeep | A | 2356914 | 228262 | 02 ноя 2022 г. |
| NIFFENEGGER KATHI | A | 4444 | 4444 | 02 ноя 2022 г. |
| NIFFENEGGER KATHI | A | 10715 | 8888 | 02 ноя 2022 г. |
| Brooks Michael J | A | 2119 | 2119 | 02 ноя 2022 г. |
Новостная лента
Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting
Accesswire
16 мар 2023 г. в 16:10
TORONTO, ON / ACCESSWIRE / March 16, 2023 / Edesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from a Phase 2B multi-dose study of its EB01 drug candidate at a Late Breaking Abstract session of the American Academy of Dermatology Association (AAD) annual meeting being held March 17-21, 2023. The presentation will detail the statistically significant topline results achieved by 1.0% EB01 cream in moderate-to-severe chronic allergic contact dermatitis (ACD) subjects, as well as data from other dose concentrations and safety data.
What Is Going on With Edesa Biotech (EDSA) Stock Today?
InvestorPlace
30 сент 2022 г. в 13:50
Amid a soft opening performance for the major equity indices, Edesa Biotech (NASDAQ: EDSA ) shot up 7% against the prior session before dipping into negative territory during the afternoon session. The biopharmaceutical company, which specializes in inflammatory and immune-related diseases, announced positive Phase 2 results for its monoclonal antibody candidate targeting respiratory symptoms.
Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference
Accesswire
08 сент 2022 г. в 16:30
TORONTO, ON / ACCESSWIRE / September 8, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference being held in New York, NY on September 12-14, 2022.
Edesa Biotech to Present at ARDS Drug Development Summit
Accesswire
11 июл 2022 г. в 08:30
TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the 2nd Annual ARDS Drug Development Summit being held July 13-15, 2022 in Boston, Mass. Dr. Nijhawan's presentation is scheduled for 8:25 am ET on July 14, 2022.